

# Jean-Pierre Pignon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8161158/publications.pdf>

Version: 2024-02-01

143  
papers

27,583  
citations

23500

58  
h-index

11288

136  
g-index

147  
all docs

147  
docs citations

147  
times ranked

21902  
citing authors

#	ARTICLE	IF	CITATIONS
1	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. <i>Radiotherapy and Oncology</i> , 2009, 92, 4-14.	0.3	2,607
2	Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 351-360.	13.9	2,161
3	Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 3552-3559.	0.8	2,119
4	Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 1715-1721.	0.8	1,696
5	DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy. <i>New England Journal of Medicine</i> , 2006, 355, 983-991.	13.9	1,611
6	Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission. <i>New England Journal of Medicine</i> , 1999, 341, 476-484.	13.9	1,562
7	Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2181-2190.	0.8	1,538
8	A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 1992, 327, 1618-1624.	13.9	1,228
9	Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. <i>Lancet</i> , The, 2006, 368, 843-854.	6.3	967
10	Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1729.	3.8	711
11	Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 47-56.	0.4	583
12	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. <i>Radiotherapy and Oncology</i> , 2011, 100, 33-40.	0.3	534
13	Survival of Patients With Resected N2 Non-Small-Cell Lung Cancer: Evidence for a Subclassification and Implications. <i>Journal of Clinical Oncology</i> , 2000, 18, 2981-2989.	0.8	472
14	A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. <i>Statistics in Medicine</i> , 2002, 21, 2641-2652.	0.8	406
15	Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. <i>Journal of Hepatology</i> , 1998, 29, 129-134.	1.8	384
16	Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 35-42.	0.8	379
17	Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 819-828.	5.1	345
18	ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 1101-1110.	13.9	342

#	ARTICLE	IF	CITATIONS
19	Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5218-5224.	0.8	321
20	Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 470.	3.8	305
21	Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 2173-2181.	0.8	270
22	Astro plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: A randomized study of 353 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 1991, 20, 1183-1190.	0.4	265
23	Taxane-Cisplatin-Fluorouracil As Induction Chemotherapy in Locally Advanced Head and Neck Cancers: An Individual Patient Data Meta-Analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 2854-2860.	0.8	253
24	Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): An Update. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S112-S114.	0.4	250
25	Initial Chemotherapeutic Doses and Survival in Patients with Limited Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 1993, 329, 1848-1852.	13.9	249
26	Hepatic and Extrahepatic Colorectal Metastases: When Resectable, Their Localization Does Not Matter, But Their Total Number Has a Prognostic Effect. <i>Annals of Surgical Oncology</i> , 2005, 12, 900-909.	0.7	240
27	Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. <i>Journal of Clinical Oncology</i> , 2015, 33, 3439-3446.	0.8	234
28	Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 2788-2797.	0.8	227
29	Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. <i>Lancet Oncology</i> , The, 2017, 18, 1221-1237.	5.1	226
30	Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2995-3006.	0.8	223
31	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 1031-1039.	0.8	216
32	Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. <i>Lancet Oncology</i> , The, 2013, 14, 619-626.	5.1	203
33	Pooled Analysis of the Effect of Age on Adjuvant Cisplatin-Based Chemotherapy for Completely Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 3573-3581.	0.8	182
34	Results of R0 Resection for Colorectal Liver Metastases Associated With Extrahepatic Disease. <i>Annals of Surgical Oncology</i> , 2004, 11, 274-280.	0.7	161
35	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. <i>Radiotherapy and Oncology</i> , 2021, 156, 281-293.	0.3	157
36	Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFC02000-05. <i>Journal of Clinical Oncology</i> , 2010, 28, 2556-2564.	0.8	146

#	ARTICLE	IF	CITATIONS
37	Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. <i>Lancet Oncology, The</i> , 2009, 10, 341-350.	5.1	138
38	Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. <i>European Journal of Cancer</i> , 2013, 49, 1565-1577.	1.3	136
39	Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1600-1607.	3.0	133
40	Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD) Tj ETQq0 0 0 rgBT /Overlock 10 T	5.1	128
41	Meta-analysis when only the median survival times are known: A comparison with individual patient data results. <i>International Journal of Technology Assessment in Health Care</i> , 2005, 21, 119-125.	0.2	124
42	Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. , 1998, 69, 88-93.		122
43	MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non-Small Cell Lung Carcinoma. <i>Cancer Research</i> , 2010, 70, 8288-8298.	0.4	121
44	Individual patients' data meta-analyses in head and neck cancer. <i>Current Opinion in Oncology</i> , 2007, 19, 188-194.	1.1	117
45	Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project. <i>Radiotherapy and Oncology</i> , 2018, 126, 107-115.	0.3	116
46	Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2012, 17, 1063-1072.	1.9	112
47	Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non-Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic Program. <i>Journal of Clinical Oncology</i> , 2007, 25, 2735-2740.	0.8	107
48	Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. <i>European Journal of Cancer</i> , 2015, 51, 166-176.	1.3	105
49	Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. <i>Lancet Oncology, The</i> , 2007, 8, 994-1000.	5.1	103
50	Quality of Life of Patients Operated on for Low Rectal Cancer: Impact of the Type of Surgery and Patients' Characteristics. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 2180-2191.	0.7	102
51	Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 2018-2027.	0.8	91
52	Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. <i>Annals of Oncology</i> , 2016, 27, 1818-1828.	0.6	88
53	Meta-analyses of randomised clinical trials in oncology. <i>Lancet Oncology, The</i> , 2001, 2, 475-482.	5.1	81
54	Fatty acid-binding protein: A major contributor to the ethanol-induced increase in liver cytosolic proteins in the rat. <i>Hepatology</i> , 1987, 7, 865-871.	3.6	78

#	ARTICLE	IF	CITATIONS
55	Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. <i>Journal of Thoracic Oncology</i> , 2016, 11, 850-861.	0.5	78
56	Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non-Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program. <i>Clinical Cancer Research</i> , 2007, 13, 3892-3898.	3.2	73
57	Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project Part 2). <i>Journal of Thoracic Oncology</i> , 2012, 7, 1490-1502.	0.5	69
58	Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. <i>Anti-Cancer Drugs</i> , 2004, 15, 331-340.	0.7	62
59	Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy. , 1998, 82, 1049-1055.		60
60	How individual participant data meta-analyses have influenced trial design, conduct, and analysis. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 1325-1335.	2.4	60
61	ERCC1 and RRM1 in the International Adjuvant Lung Trial by Automated Quantitative in Situ Analysis. <i>American Journal of Pathology</i> , 2011, 178, 69-78.	1.9	59
62	Catalytic Subunit of Human Telomerase Reverse Transcriptase Is an Independent Predictor of Survival in Patients Undergoing Curative Resection of Hepatic Colorectal Metastases: A Multicenter Analysis. <i>Journal of Clinical Oncology</i> , 2005, 23, 3086-3093.	0.8	57
63	Need for a New Trial to Evaluate Adjuvant Postoperative Radiotherapy in Non-Small-Cell Lung Cancer Patients With N2 Mediastinal Involvement. <i>Journal of Clinical Oncology</i> , 2007, 25, e10-e11.	0.8	55
64	Extrapolation of Survival Curves from Cancer Trials Using External Information. <i>Medical Decision Making</i> , 2017, 37, 353-366.	1.2	48
65	Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 727-736.	5.1	45
66	Apolipoprotein AI and alcoholic liver disease. <i>Hepatology</i> , 1986, 6, 1391-1395.	3.6	44
67	Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. <i>BMJ Open</i> , 2013, 3, e001802.	0.8	43
68	Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. <i>European Journal of Cancer</i> , 2021, 145, 221-229.	1.3	42
69	Chemotherapy for Nasopharyngeal Carcinoma Current Recommendation and Controversies. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 1107-1122.	0.9	39
70	Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: Contribution of the International Adjuvant Lung Trial. <i>Clinical Cancer Research</i> , 2005, 11, 5017s-5021s.	3.2	38
71	A joint model for the dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer. <i>Statistical Methods in Medical Research</i> , 2015, 24, 711-729.	0.7	37
72	Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	37

#	ARTICLE	IF	CITATIONS
73	Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: A meta-analysis. , 1996, 77, 2413-2414.		35
74	Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies â€” The Pre-Optimon study. Contemporary Clinical Trials, 2011, 32, 16-24.	0.8	34
75	A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit From Adjuvant Platinum-Based Chemotherapy in Node-Negative Nonâ€”Small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 963-972.	0.5	33
76	Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. Lung Cancer, 2012, 76, 78-83.	0.9	33
77	Prognostic value of serum fibronectin concentration in alcoholic cirrhotic patients. Hepatology, 1985, 5, 819-823.	3.6	32
78	A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Nonâ€”Small Cell Lung Cancer Settingâ€”IFCT/ERMETIC2 Project Part 1. Journal of Molecular Diagnostics, 2014, 16, 45-55.	1.2	31
79	Estimating Number of Events from the Kaplan-Meier Curve for Incorporation in a Literature-Based Meta-Analysis: What You Don't See You Can't Get!. Biometrics, 2000, 56, 886-892.	0.8	30
80	Joint Model for Left-Censored Longitudinal Data, Recurrent Events and Terminal Event: Predictive Abilities of Tumor Burden for Cancer Evolution With Application to the FFCD 2000â€”05 Trial. Biometrics, 2016, 72, 907-916.	0.8	28
81	Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. BMC Medical Research Methodology, 2016, 16, 37.	1.4	28
82	Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. , 2007, , CD004569.		26
83	Apolipoprotein A1 is a Serum and Tissue Marker of Liver Fibrosis in Alcoholic Patients. Alcoholism: Clinical and Experimental Research, 1989, 13, 829-833.	1.4	25
84	Initial Chemotherapeutic Doses and Long-Term Survival in Limited Small-Cell Lung Cancer. New England Journal of Medicine, 2001, 345, 1281-1282.	13.9	24
85	Gender Differences in the Response of Hepatic Fatty Acids and Cytosolic Fatty Acid-Binding Capacity to Alcohol Consumption in Rats. Experimental Biology and Medicine, 1991, 198, 584-590.	1.1	23
86	Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes. JAMA Oncology, 2020, 6, 206.	3.4	22
87	Should adjuvant chemotherapy become standard treatment in all patients with resected non-small-cell lung cancer?. Lancet Oncology, The, 2005, 6, 182-184.	5.1	21
88	LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Nonâ€”small-cell Lung Cancer. Clinical Lung Cancer, 2019, 20, 66-73.e6.	1.1	19
89	Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. Oral Oncology, 2019, 95, 106-114.	0.8	18
90	Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients. Clinical and Translational Radiation Oncology, 2022, 32, 59-68.	0.9	18

#	ARTICLE	IF	CITATIONS
91	Chemotherapy in Non-Small-Cell Lung Cancer: An Update of an Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2005, 23, 924-925.	0.8	17
92	The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study. <i>Supportive Care in Cancer</i> , 2009, 17, 1255-1261.	1.0	17
93	Chemotherapy in non-small cell lung cancer: An update of an individual patient data-based meta-analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 129, 1205.	0.4	16
94	Evaluation of heart murmurs in chinchillas ( <i>Chinchilla lanigera</i> ): 59 cases (1996-2009). <i>Journal of the American Veterinary Medical Association</i> , 2012, 241, 1344-1347.	0.2	16
95	Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non-Small-Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1295-1307.	0.5	16
96	Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival. <i>Journal of Neuro-Oncology</i> , 2015, 123, 307-314.	1.4	16
97	A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 15924-15933.	0.8	16
98	Use of Adjuvant Chemotherapy in Non-small Cell Lung Cancer in Routine Practice. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1504-1510.	0.5	15
99	Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 8,221 patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6523-6523.	0.8	14
100	Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases. <i>European Journal of Cancer</i> , 2020, 138, 89-98.	1.3	13
101	Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study. <i>PLoS ONE</i> , 2016, 11, e0150032.	1.1	13
102	Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 25189-25199.	0.8	12
103	Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival. <i>Radiation Oncology</i> , 2011, 6, 124.	1.2	11
104	Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 416-427.	1.3	11
105	Predictive classifier for intensive treatment of head and neck cancer. <i>Cancer</i> , 2020, 126, 5263-5273.	2.0	11
106	Clinical Research Infrastructures and Networks in France: Report on the French ECRIN Workshop. <i>Therapie</i> , 2005, 60, 183-199.	0.6	10
107	Role of meta-analyses and of large randomized trials in the study of cancer treatments. <i>Lung Cancer</i> , 2009, 65, 9-12.	0.9	10
108	Resected non-small cell lung cancer: need for adjuvant lymph node treatment? From hope to reality. <i>Lung Cancer</i> , 2003, 42, 57-64.	0.9	9

#	ARTICLE	IF	CITATIONS
109	Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA. <i>Lung Cancer</i> , 2013, 82, 149-155.	0.9	8
110	Concordance measures in shared frailty models: application to clustered data in cancer prognosis. <i>Statistics in Medicine</i> , 2013, 32, 4803-4820.	0.8	8
111	Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology. <i>Computational and Mathematical Methods in Medicine</i> , 2018, 2018, 1-8.	0.7	8
112	Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction. <i>European Journal of Cancer</i> , 2021, 157, 278-290.	1.3	8
113	Early stopping rules and long-term follow-up in Phase III trials. <i>Lung Cancer</i> , 1994, 10, S151-S159.	0.9	7
114	Individual patient data meta-analysis of prophylactic cranial irradiation in locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2021, 158, 40-47.	0.3	7
115	Triangular test and randomized trials: Practical problems in a small cell lung cancer trial. <i>Statistics in Medicine</i> , 1994, 13, 1415-1421.	0.8	6
116	Meta-analyses of randomized clinical trials: how to improve their quality?. <i>Lung Cancer</i> , 1994, 10, S135-S141.	0.9	6
117	Letter to the editor. <i>Lung Cancer</i> , 2005, 48, 149-150.	0.9	5
118	Comment on "Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature" by T. Berghmans, M. Paesmans, A.P. Meert, C. Mascaux, P. Lothaire, J.J. Lafitte, et al. [ <i>Lung Cancer</i> 49 (2005) 13-23]. <i>Lung Cancer</i> , 2006, 51, 261-262.	0.9	5
119	Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: A non-comparative randomized phase II trial. <i>Digestive and Liver Disease</i> , 2014, 46, 950-955.	0.4	5
120	Comment on "Bayesian network meta-analysis of chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: published in <i>Eur J Cancer</i> 51 (2015), 1570-1579. <i>European Journal of Cancer</i> , 2016, 56, 183-185.	1.3	5
121	In reply to Drs. Huncharek and Kupelnick. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 958-959.	0.4	4
122	Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. , 1998, 69, 88.		4
123	Antiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. <i>European Journal of Cancer</i> , 2022, 166, 112-125.	1.3	4
124	Is Meta-analysis a Metaphysical or a Scientific Method?. <i>Chest</i> , 2000, 118, 832-834.	0.4	3
125	Cost-Effectiveness Analysis of First-Line Chemotherapies in Metastatic Colorectal Cancer. <i>Oncology</i> , 2006, 71, 40-48.	0.9	3
126	Are Individual patient data meta-analyses still needed today in oncology? A discussion focused on Head and Neck oncology. <i>Acta Oncologica</i> , 2019, 58, 1333-1336.	0.8	3



#	ARTICLE	IF	CITATIONS
127	Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2). <i>Clinical Lung Cancer</i> , 2019, 20, 222-230.	1.1	3
128	A frequentist one-step model for a simple network meta-analysis of time-to-event data in presence of an effect modifier. <i>PLoS ONE</i> , 2021, 16, e0259121.	1.1	3
129	Controversies in the management of small cell lung cancer: thoracic radiotherapy in limited disease. <i>Lung Cancer</i> , 1993, 9, 253-263.	0.9	2
130	Of scientific physicians and objective knowledge. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 1140-1141.	0.4	2
131	Altered fractionated radiotherapy in head and neck cancer – Authors' reply. <i>Lancet</i> , The, 2006, 368, 1868.	6.3	2
132	Preoperative chemotherapy for non-small-cell lung cancer – Authors' reply. <i>Lancet</i> , The, 2014, 384, 233.	6.3	2
133	Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block?. <i>European Journal of Cancer</i> , 2016, 69, 178-179.	1.3	2
134	C3-05: Chemotherapy (CT) in addition to surgery or surgery plus radiotherapy (RT) in non-small cell lung cancer (NSCLC): Two meta-analyses using individual patient data (IPD) from randomised controlled trials (RCTs). <i>Journal of Thoracic Oncology</i> , 2007, 2, S366-S367.	0.5	2
135	Reply to S.D. Richman et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e356-e357.	0.8	1
136	Meta-analysis of prognostic and predictive factors: Towards individual participant data?. <i>European Journal of Cancer</i> , 2018, 104, 224-226.	1.3	1
137	Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 601-608.	0.7	1
138	The role of chest irradiation in small cell lung cancer. <i>Cancer Treatment and Research</i> , 1994, 72, 255-271.	0.2	1
139	Proposal for a new section in Lung Cancer on ongoing randomized trials. <i>Lung Cancer</i> , 1994, 11, 401-403.	0.9	0
140	Chemotherapy for colorectal cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2012, 13, e4.	5.1	0
141	Reply to – Interpretation of concordance measures for clustered data™. <i>Statistics in Medicine</i> , 2014, 33, 717-718.	0.8	0
142	Reply to D. Tural et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 259-260.	0.8	0
143	Response to R. Jayaraj. <i>Oral Oncology</i> , 2020, 102, 104439.	0.8	0